ERYTECH receives authorization to start its Phase II clinical study in pancreatic cancer Post author:admERY Post published:May 6, 2014 Post category:Newsroom ERYTECH announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer. You Might Also Like ERYTECH wins the European Small and Mid-Cap Award in the Most Innovative Newcomer category December 10, 2015 ERYTECH provides financial update for Q3 2013 November 5, 2013 ERYTECH provides financial update for Q1 2014 May 15, 2014
ERYTECH wins the European Small and Mid-Cap Award in the Most Innovative Newcomer category December 10, 2015